Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 30:15:1399802.
doi: 10.3389/fphar.2024.1399802. eCollection 2024.

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future

Harriet Lampe  1 , Laura Tam  1 , Aaron R Hansen  1
Affiliations
Review

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future

Harriet Lampe et al. Front Pharmacol. .

Abstract

Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of novel immunotherapies with demonstrated success in haematological malignancies and melanoma. BiTEs developed for tumour associated antigens in prostate cancer have entered clinical testing. These trials have been hampered by high rates of treatment related adverse events, minimal or transient anti-tumour efficacy and generation of high titres of anti-drug antibodies. This paper aims to analyse the challenges faced by the different BiTE therapy constructs and the mCRPC tumour microenvironment that result in therapeutic resistance and identify possible strategies to overcome these issues.

Keywords: BiTE; T-cell engager therapy; bi-specific T-cell engager therapy; bi-specific antibody therapy; metastatic castrate resistant prostate cancer; novel immunotherapies; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Administration USFaD (2010) Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection - guidelines for Industry.
    1. Agency E. M. (2017) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins.
    1. Aggarwal R. R., Aparicio A., Heidenreich A., Sandhu S. K., Zhang Y., Salvati M., et al. (2021). Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). J. Clin. Oncol. 39 (15), TPS5100. 10.1200/jco.2021.39.15_suppl.tps5100 - DOI
    1. Ahmad Z. A., Yeap S. K., Ali A. M., Ho W. Y., Alitheen N. B., Hamid M. (2012). scFv antibody: principles and clinical application. Clin. Dev. Immunol. 2012, 980250. 10.1155/2012/980250 - DOI - PMC - PubMed
    1. Antonarakis E. S., Shaukat F., Isaacsson Velho P., Kaur H., Shenderov E., Pardoll D. M., et al. (2019). Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur. Urol. 75 (3), 378–382. 10.1016/j.eururo.2018.10.009 - DOI - PMC - PubMed

LinkOut - more resources